Lv4
418 积分 2024-09-29 加入
An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma
2天前
已完结
Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma
13天前
已完结
Pathological studies of intervertebral discs
17天前
已关闭
Management of Carfilzomib-Associated Cardiac Adverse Events
17天前
已完结
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
18天前
已关闭
[Guidelines for the diagnosis and management of multiple myeloma in China (2024 revision)]
25天前
已完结
Identifying high‐risk multiple myeloma patients: A novel approach using a clonal gene signature
1个月前
已完结
High‐risk multiple myeloma: Redefining genetic, clinical, and functional high‐risk disease in the era of molecular medicine and immunotherapy
1个月前
已完结
Chromosomal defects in multiple myeloma
1个月前
已完结
Multiple myeloma
1个月前
已完结
皖公网安备34019202002308
